{
  "report_rows": [
    {
      "kpi": "CAG Diagnostics Recurring Revenue (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$975M vs. cons $962.9M",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Operating EPS Diluted (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$3.98 vs. cons $3.92",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Total Revenue (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$1,210M vs. cons $1,198.3M",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY 2026 Revenue (FY 2026)",
      "prediction": "BETTER",
      "answer": "guide mid ~$4,745M vs. cons $4,705.5M",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY 2026 Operating EPS (FY 2026)",
      "prediction": "BETTER",
      "answer": "guide mid ~$14.83 vs. cons $14.66",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FNA Ramp Commentary",
      "prediction": "UNCHANGED",
      "answer": "on track / broadening vs. on track expected",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Clinical Visit Assumption (FY 2026)",
      "prediction": "UNCHANGED",
      "answer": "maintain -1.5% vs. -1.5% expected",
      "confidence": "HIGH"
    }
  ],
  "day1_residual_pct": 6.0,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 9.0,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "FOLLOW-THROUGH \u2014 sell-side estimate revisions on genuine FY raise force upward drift; FNA ramp narrative sustains bid",
  "day5_confidence": "MEDIUM"
}